ESSA Pharma
EPIX
EPIX was delisted on the 8th of October, 2025.
32 hedge funds and large institutions have $4.3M invested in ESSA Pharma in 2025 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 8 increasing their positions, 8 reducing their positions, and 12 closing their positions.
126% more call options, than puts
Call options by funds: $165K | Put options by funds: $73K
0% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 8
11% less funds holding
Funds holding: 36 → 32 (-4)
22.17% less ownership
Funds ownership: 69.77% → 47.61% (-22%)
33% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 12
92% less capital invested
Capital invested by funds: $52.7M → $4.3M (-$48.3M)
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$3.5M |
| 2 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$2.52M |
| 3 |
SC
Shay Capital
New York
|
+$614K |
| 4 |
LP
LMR Partners
London,
United Kingdom
|
+$409K |
| 5 |
Two Sigma Investments
New York
|
+$136K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
-$7.31M |
| 2 |
BCM
BML Capital Management
Zionsville,
Indiana
|
-$7.18M |
| 3 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$3.76M |
| 4 |
Morgan Stanley
New York
|
-$2.76M |
| 5 |
AC
Aldebaran Capital
Carmel,
Indiana
|
-$984K |
EPIX Hedge Fund Activity: Q3 2025 in Review
32 of the 7,638 institutional investors tracked by Wall St. Rank reported a position in ESSA Pharma (EPIX) for Q3 2025, worth a combined $4.3M — down 92% from $52.7M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of EPIX and 8 opened new positions — a net loss of 4 holders — while 8 trimmed existing stakes and 8 added.
The largest buyer was BVF Inc, adding an estimated $3.5M. The largest seller was Tang Capital Management, exiting entirely with an estimated $7.31M sold.
- 32 institutional investors held ESSA Pharma (EPIX) as of Q3 2025, down from 36 in Q2 2025.
- Funds reported $4.3M of ESSA Pharma stock for Q3 2025, down 92% quarter-over-quarter.
- 8 funds opened new ESSA Pharma positions in Q3 2025 and 12 closed out, a net change of -4 holders.
- The largest ESSA Pharma buyer in Q3 2025 was BVF Inc, an estimated $3.5M added.
- The largest ESSA Pharma seller in Q3 2025 was Tang Capital Management, an estimated $7.31M sold.
Based on aggregated 13F filings for Q3 2025.